Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2008-11-14

FDA Approved: BANZEL — Original Application (Eisai Inc.)

View source ↗

Summary

FDA approves BANZEL (rufinamide) in an original application for treatment of seizures associated with Lennox-Gastaut syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Banzel (rufinamide)

Snippet

ORIG AP for BANZEL (RUFINAMIDE)